Kepler Capital Markets set a €89.00 ($104.71) price objective on Sanofi SA (EPA:SAN) in a report issued on Wednesday, July 26th. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also weighed in on the company. J P Morgan Chase & Co set a €95.00 ($111.76) target price on Sanofi SA and gave the stock a neutral rating in a report on Thursday, June 22nd. Jefferies Group LLC set a €92.00 ($108.24) price target on Sanofi SA and gave the stock a neutral rating in a research report on Monday, May 29th. Credit Suisse Group set a €95.00 ($111.76) price target on Sanofi SA and gave the stock a buy rating in a research report on Tuesday, July 4th. Berenberg Bank set a €97.00 ($114.12) price target on Sanofi SA and gave the stock a neutral rating in a research report on Thursday, May 11th. Finally, Morgan Stanley set a €91.00 ($107.06) price target on Sanofi SA and gave the stock a buy rating in a research report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company’s stock. Sanofi SA presently has an average rating of Hold and an average target price of €87.63 ($103.09).
Sanofi SA (EPA SAN) traded up 0.99% during mid-day trading on Wednesday, hitting €82.58. 1,485,160 shares of the stock were exchanged. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The company has a 50-day moving average price of €25.48 and a 200-day moving average price of €25.74. The company has a market cap of €103.70 billion and a P/E ratio of 11.52.
TRADEMARK VIOLATION WARNING: “Sanofi SA (EPA:SAN) PT Set at €89.00 by Kepler Capital Markets” was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/16/kepler-capital-markets-reiterates-89-00-price-target-for-sanofi-sa-epasan-updated-updated.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi SA and related companies with MarketBeat.com’s FREE daily email newsletter.